{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:29:14Z","timestamp":1791559754803,"version":"4.3.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2020M681792"],"award-info":[{"award-number":["2020M681792"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872734"],"award-info":[{"award-number":["81872734"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204195"],"award-info":[{"award-number":["82204195"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173674"],"award-info":[{"award-number":["82173674"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejmech.2023.116032","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T12:51:56Z","timestamp":1701953516000},"page":"116032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Design, synthesis and bioactivity evaluation of novel fusion peptides and their CPT conjugates inducing effective anti-tumor responses on HER2 positive tumors"],"prefix":"10.1016","volume":"264","author":[{"given":"Jiaqi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhancheng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeqi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qimeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3827-0992","authenticated-orcid":false,"given":"Hai","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.116032_bib1","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3389\/fonc.2019.01308","article-title":"Epidermal growth factor receptor family and its role in gastric cancer","volume":"9","author":"Arienti","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2023.116032_bib2","doi-asserted-by":"crossref","first-page":"14843","DOI":"10.1073\/pnas.232580999","article-title":"Nrdp1\/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3","volume":"99","author":"Qiu","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2023.116032_bib3","doi-asserted-by":"crossref","first-page":"8690","DOI":"10.1016\/j.biomaterials.2013.07.100","article-title":"Epidermal growth factor receptor targeting in cancer: a review of trends and strategies","volume":"34","author":"Yewale","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejmech.2023.116032_bib4","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2023.116032_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF00918679","article-title":"Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic","volume":"11","author":"Shepard","year":"1991","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.116032_bib6","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/eji.1830270511","article-title":"The HER2\/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes","volume":"27","author":"Peiper","year":"1997","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejmech.2023.116032_bib7","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.2147\/OTT.S312820","article-title":"Progress in treatment of non-small cell lung cancer harboring HER2 aberrations","volume":"14","author":"Ni","year":"2021","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2023.116032_bib8","doi-asserted-by":"crossref","first-page":"10343","DOI":"10.2147\/OTT.S230309","article-title":"Recent progress in rare oncogenic drivers and targeted therapy for non-small cell lung cancer","volume":"12","author":"Guo","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2023.116032_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int"},{"key":"10.1016\/j.ejmech.2023.116032_bib10","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1002\/cncr.33102","article-title":"Novel HER2-targeted therapies for HER2-positive metastatic breast cancer","volume":"126","author":"Kunte","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2023.116032_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00005-019-00566-1","article-title":"HER2-Positive breast cancer immunotherapy: a focus on vaccine development","volume":"68","author":"Arab","year":"2020","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.ejmech.2023.116032_bib12","doi-asserted-by":"crossref","first-page":"103997","DOI":"10.1016\/j.critrevonc.2023.103997","article-title":"A review of HER2 overexpression and somatic mutations in cancers","volume":"186","author":"Galogre","year":"2023","journal-title":"Crit. Rev. Oncol.-Hematol."},{"key":"10.1016\/j.ejmech.2023.116032_bib13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0958-1669(02)00348-8","article-title":"Monoclonal antibodies as therapeutics in oncology","volume":"13","author":"Trikha","year":"2002","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ejmech.2023.116032_bib14","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1951427","article-title":"Targeting cancer with antibody-drug conjugates: promises and challenges","volume":"13","author":"Dean","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.ejmech.2023.116032_bib15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2010.04.009","article-title":"The role of HER2 in cancer therapy and targeted drug delivery","volume":"146","author":"Tai","year":"2010","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2023.116032_bib16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/19420862.2018.1541370","article-title":"Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models","volume":"11","author":"Kuo","year":"2019","journal-title":"mAbs"},{"key":"10.1016\/j.ejmech.2023.116032_bib17","article-title":"Comparative efficacy of tyrosine kinase inhibitors and antibody-drug conjugates in HER2-positive metastatic breast cancer patients with brain metastases: a systematic review and network meta-analysis","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2023.116032_bib18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/CM9.0000000000001932","article-title":"Antibody-drug conjugates in HER2-positive breast cancer","volume":"135","author":"Li","year":"2021","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.ejmech.2023.116032_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13058-021-01459-y","article-title":"Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions","volume":"23","author":"Ferraro","year":"2021","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejmech.2023.116032_bib20","article-title":"HER2-targeted therapies in gastric cancer","volume":"1876","author":"Zhu","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejmech.2023.116032_bib21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.116032_bib22","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejmech.2023.116032_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Tar"},{"key":"10.1016\/j.ejmech.2023.116032_bib24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.addr.2016.06.015","article-title":"Peptide-drug conjugates as effective prodrug strategies for targeted delivery","volume":"110\u2013111","author":"Wang","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2023.116032_bib25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/17425247.2022.2039621","article-title":"The development of peptide-drug conjugates (PDCs) strategies for paclitaxel","volume":"19","author":"Wang","year":"2022","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.ejmech.2023.116032_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27217232","article-title":"Peptide-drug conjugates: a new hope for cancer management","volume":"27","author":"Chavda","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2023.116032_bib27","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.2174\/0929867324666170404142840","article-title":"Peptide-drug conjugate: a novel drug design approach","volume":"24","author":"Ma","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116032_bib28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1756-8722-5-70","article-title":"Targeted drug delivery for cancer therapy: the other side of antibodies","volume":"5","author":"Firer","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2023.116032_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.dmpk.2018.11.001","article-title":"Pharmacokinetics of protein and peptide conjugates","volume":"34","author":"Bumbaca","year":"2019","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2023.116032_bib30","doi-asserted-by":"crossref","first-page":"15123","DOI":"10.1021\/acs.jmedchem.2c00968","article-title":"Exploration and biological evaluation of bispecific peptides derived from anti-HER2 antibodies and peptide-camptothecin conjugates for HER2-positive breast cancer","volume":"65","author":"Zhou","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116032_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0092-8674(00)00008-8","article-title":"Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition","volume":"102","author":"Du","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.116032_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020406","article-title":"Future therapeutic directions for smac-mimetics","volume":"9","author":"Morrish","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2023.116032_bib33","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2174\/157340608784872217","article-title":"A novel polyarginine containing smac peptide conjugate that mediates cell death in tumor and healthy cells","volume":"4","author":"Heckl","year":"2008","journal-title":"Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423009996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423009996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:06:11Z","timestamp":1759331171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423009996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":33,"alternative-id":["S0223523423009996"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.116032","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and bioactivity evaluation of novel fusion peptides and their CPT conjugates inducing effective anti-tumor responses on HER2 positive tumors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.116032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116032"}}